Connect with us

INDUSTRIAL HEMP

Digipath Inc. (OTCMKTS: DIGP) Announce Significant Milestones On Development Of GroSciences Hemp-Test Kit

Published

on

Digipath Inc. (OTCMKTS:DIGP) has announced that its GroSciences subsidiary has made substantial progress in the development of its Tru-Hemp ID project that is targeted for commercial availability at the end of this year or early 2020.

GroSciences announce the development of the hemp-testing kit

GroSciences is a wholly-owned subsidiary of Digipath that uses proprietary research and data testing experience to come up with “The Science to Succeed” for its clients who are looking for expert guidance on identification and formulations. Digipath recently announced that it is developing field testing kit through its subsidiary GroSciences. The kit tests for cannabis, hemp, and other products and it has many applications and it can be used by farmers and law enforcement.

The subsidiary has so far completed the initial testing of the Tru-Hemp ID at two different facilities. Tru-Hemp is a DNA-based test kit that has the capability of distinguishing legal industrial hemp from street type cannabis. The kit will be vital in addressing the growing need in the fast-growing hemp industry since it is not easy to distinguish legal industrial hemp from high-THC cannabis which is a Schedule I Controlled Substance.

Beta-test for the Tru-Hemp ID kit in August

GroSciences is currently planning a beta-test for Tru-Hemp ID kit in New York, Vermont, and North Carolina as from August. The company is also in talks with regulators and growers from Colorado, Oregon, and California to test the kit.

Digipath Chief Science Officer, Dr. Cindy Orser indicated that the company has made significant milestones in the development of the Tru-Hemp ID. Cindy said that besides the developing of the technology that the Tru-Hemp test kit uses the company has also partnered with leading hemp farmers to carry out independent testing of the technology. She adds that that will be vital in accelerating the company’s path to commercial availability of the testing kit.

According to the CEO of Digipath Todd Denkin, the deployment of the testing kit in the commercial market place will be a good revenue stream for the company.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.